Literature DB >> 17014925

Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population.

Sun Ha Park1, Jin Eun Choi, Eun Jin Kim, Jin Sung Jang, Won Kee Lee, Sung Ick Cha, Chang Ho Kim, Sin Kam, Dong Sun Kim, Rang-Woon Park, Young-Chul Kim, Sung Beom Han, Tae Hoon Jung, Jae Yong Park.   

Abstract

BACKGROUND: The FAS and FASL system play an important role in regulating extrinsic apoptotic pathway and inappropriate regulation of this signaling pathway contributes to lung tumorigenesis. Polymorphisms in the promoter region of the FAS (-1377G>A and -670A>G) and FASL (-844C>T) have been shown to alter the transcriptional activities of these genes. In order to evaluate the contribution of these polymorphisms to the risk of lung cancer, we carried out a case-control study in a Korean population.
METHODS: The FAS and FASL genotypes were determined in 582 lung cancer patients and 582 healthy control subjects who were frequency-matched for age and gender.
RESULTS: The FAS and FASL genotypes and the FAS haplotypes exhibited no apparent relationship with the risk of lung cancer. In addition, there was no significant interaction between the FAS and FASL polymorphisms in the development of lung cancer.
CONCLUSION: These results suggest that the FAS-1377G>A and -670A>G and FASL-844C>T polymorphisms do not significantly affect the susceptibility to lung cancer in Koreans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17014925     DOI: 10.1016/j.lungcan.2006.09.002

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  17 in total

1.  Comprehensive assessment of P21 polymorphisms and lung cancer risk.

Authors:  Yi Young Choi; Hyo-Kyung Kang; Jin Eun Choi; Jin Sung Jang; Eun Jin Kim; Sung Ick Cha; Won Kee Lee; Sin Kam; Chang Ho Kim; Sung Beom Han; Tae Hoon Jung; Jae Yong Park
Journal:  J Hum Genet       Date:  2007-11-28       Impact factor: 3.172

2.  FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls.

Authors:  Li-Xin Qiu; Jian Shi; Hui Yuan; Xin Jiang; Kai Xue; Hai-Feng Pan; Jin Li; Ming-Hua Zheng
Journal:  Hum Genet       Date:  2009-02-19       Impact factor: 4.132

3.  International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants.

Authors:  Therese Truong; Wiebke Sauter; James D McKay; H Dean Hosgood; Carla Gallagher; Christopher I Amos; Margaret Spitz; Joshua Muscat; Philip Lazarus; Thomas Illig; H Erich Wichmann; Heike Bickeböller; Angela Risch; Hendrik Dienemann; Zuo-Feng Zhang; Behnaz Pezeshki Naeim; Ping Yang; Shanbeh Zienolddiny; Aage Haugen; Loïc Le Marchand; Yun-Chul Hong; Jin Hee Kim; Eric J Duell; Angeline S Andrew; Chikako Kiyohara; Hongbing Shen; Keitaro Matsuo; Takeshi Suzuki; Adeline Seow; Daniel P K Ng; Qing Lan; David Zaridze; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Vali Constantinescu; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Neil E Caporaso; Demetrius Albanes; Michael Thun; Maria Teresa Landi; Joanna Trubicka; Marcin Lener; Jan Lubinski; Ying Wang; Amélie Chabrier; Paolo Boffetta; Paul Brennan; Rayjean J Hung
Journal:  Carcinogenesis       Date:  2010-01-27       Impact factor: 4.944

4.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

5.  Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer.

Authors:  Monica Ter-Minassian; Rihong Zhai; Kofi Asomaning; Li Su; Wei Zhou; Geoffrey Liu; Rebecca Suk Heist; Thomas J Lynch; John C Wain; Xihong Lin; Immaculata De Vivo; David C Christiani
Journal:  Carcinogenesis       Date:  2008-08-29       Impact factor: 4.944

6.  The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.

Authors:  Zhizhong Zhang; Lixin Qiu; Meilin Wang; Na Tong; Jin Li; Zhengdong Zhang
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

7.  Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.

Authors:  Aziati Azwari Annuar; Ravindran Ankathil; Nazihah Mohd Yunus; Azlan Husin; Nur Shafawati Ab Rajab; Ahmad Aizat Abdul Aziz; Mohd Ismail Ibrahim; Sarina Sulong
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

8.  CD95 rs1800682A/G variant and tumor risk in Asians: evidence from a meta-analysis of 36 case-control studies containing 22,438 samples.

Authors:  Cheng Jin; Xiaomin Wu; Yuanlong Gu; Fenglai Yuan; Qinghai Ye; Feng Dai; Lijie Zhu; Yuanyuan Mi
Journal:  Med Sci Monit       Date:  2015-02-27

9.  FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.

Authors:  Hongguang Zhao; Wenhu Chen; Peng Du; Aihua Sun; Chenyu Zhuang; Jiali Tong; Lifang Wang
Journal:  Tumour Biol       Date:  2015-01-18

10.  Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study.

Authors:  Jin Eun Choi; Sun Ha Park; Kyung Mee Kim; Won Kee Lee; Sin Kam; Sung Ick Cha; Chang Ho Kim; Young Mo Kang; Young-Chul Kim; Sung Beom Han; Tae Hoon Jung; Jae Yong Park
Journal:  BMC Cancer       Date:  2007-10-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.